Notch Therapeutics
Notch Therapeutics Employees
17 people indexed:
-
22y2@5zq76g6.w8q Sign up to see email
-
s9sk9ji@6uklq2v.8gu Sign up to see email
-
rj86f@ji2808f.fyi Sign up to see email
-
z2b1i4@wz9200b.1pv Sign up to see email
-
vq8se@buvw848.ekk Sign up to see email
-
Elaine Walton
Associate Director, Contracts & Legal Affairs
4iyz37s@zpjgsk9.yzy Sign up to see emailkyjz1bp@4kd69qy.80d Sign up to see email -
fj2f3z@b7yd76q.zaa Sign up to see email
-
Kamran Alam
Executive Vice President, Finance & Chief Financial Officer
rjqzy@e89qpz4.3vf Sign up to see emailq0vv3@u1wfyuz.6qb Sign up to see email -
71zp9a@0j33uri.ipl Sign up to see email
-
vivp80gb@qv9dg46.6d7 Sign up to see email
-
38fdd5f3@7kw5i95.9qf Sign up to see email
-
Muluken Belew
Associate Director of Preclinical Translational Sciences
iq9rg9@du4d705.az3 Sign up to see email4fqf9f@i27a3g0.1vg Sign up to see email -
2f8z3z@b5fr9yg.bzr Sign up to see email
-
Siddarth Chandrasekaran
Associate Director, Cancer Biology and Translational Sciences
63y16g15945wpvl@lwz2lbi.96v Sign up to see emailj4ul2y6vb2bvvjj@gwz2ll1.bgv Sign up to see email -
a5b@ji0q9ia.6pz Sign up to see email
-
8g6a6zgb2@1081ak9.j2u Sign up to see email
-
6wsi@3iqgsv5.gj1 Sign up to see email
Notch Therapeutics Company Information
Notch Therapeutics, a biotechnology firm, specializes in developing cellular immunotherapies from engineered pluripotent stem cells aimed at treating complex diseases, with a primary focus on cancer. The company emphasizes transformational cell therapies that surpass current standards of care. Notch Therapeutics employs innovative technologies to generate an unlimited supply of therapeutic cells from pluripotent stem cells. The company operates out of offices in Vancouver, Seattle, and Toronto and has developed a proprietary T cell-production platform that integrates product design with processes compatible for commercial scale. In February 2021, Notch Therapeutics raised $85 million in Series A financing. The company collaborates with Allogene Therapeutics to advance iPSC-derived T cells for treating hematological malignancies and maintains partnerships with the Sunnybrook Research Institute and the University of Toronto.